Pfizer CEO Albert Bourla joins CNBC's 'Special Report' as President-elect Donald Trump is inaugurated as the 47th U.S.

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

The MRHA, which overseas the safety of medicines, vaccines and healthcare devices, was accused of not acting fast enough when ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

But it's still worth ironing out the kinks in your investing habits, especially if you plan to be investing for decades to ...

Pfizer Inc (PFE) stock saw a decline, ending the day at $26.3 which represents a decrease of $-0.19 or -0.72% from the prior close of $26.49. The stock opened at $26.4 and touched a low of $26.22 ...

Sir Chris Whitty tells the Covid-19 Inquiry the NHS has 'slipped backwards' since the pandemic at sharing vital patient data, ...

We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential. In this article, we are going to take a ...

MHRA’s independence also questioned during Commons debate, with regulator accused of being too close to companies it ...